[Intraerythrocyte levels of glucose-6-phosphate dehydrogenase in patients with essential arterial hypertension and persons with normal blood pressure. Modifications after nifedipine therapy].
We evaluate the levels of intra-erythrocytes glucose-6-phosphate-dehydrogenase (G6PD) in a group of 50 patients with essential blood hypertension (EBH) (214.76 +/- 38.31 mU/ml) and in a group of 50 healthy persons (130.11 +/- 49.50 mU/ml) (p minor of 0.0005). At the same time, we have analysed the intraerythrocyte levels of G6PD of 34 healthy sons and daughters of hypertensive parents, detecting high levels in 13 of them. We observed a significant decrease of G6PD after the therapy with nifedipine in 20 hypertensive patients (p less than 0.0005). We conclude that measurement of G6PD enzyme activity can prove to be a good marker of essential hypertension. This change occurs at an early stage and is noticeable in high risk persons with family predisposition. It is possible to modify levels by working on cation changes through membrane cells by calcium-antagonist.
Pérez Cano
R
R
Departamento de Medicina, Hospital Clínico Universitario, Sevilla.
Murillo del Castillo
C
C
Montoya García
M J
MJ
Olivan Martínez
J
J
Moruno García
R
R
Galán Galán
F
F
Garrido Peralta
M
M
D000328:Adult; D000368:Aged; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D005954:Glucosephosphate Dehydrogenase / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*
D005954:Glucosephosphate Dehydrogenase; D009543:Nifedipine
Niveles intraeritrocitarios de glucosa 6 fosfato deshidrogenasa en pacientes con hipertensión arterial esencial y sujetos normotensos. Modificaciones después del tratamiento con nifedipina.